Adam Feuerstein

TheStreet.com Senior Columnist

Before joining TheStreet.com in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

Feuerstein graduated from Emory University with a bachelor's degree in political science.

Adam Feuerstein
By This Author:
Page 2 of 405
Article

Poniard Finds Cash to Keep Lights On: BioBuzz

By Adam Feuerstein

Poniard faces a cash-crunch situation after a failed drug test last week.

12:59PM 11/23/09

Article

Cel-Sci Chairman Sells Stock, Despite Sweetheart Loan Deal: BioBuzz

By Adam Feuerstein

Shareholders are on the hook for a generous loan repayment to Cel-Sci's founder.

10:14AM 11/23/09

Article

FDA Issues New Obesity Drug Heart Warning: BioBuzz

By Adam Feuerstein

Safety of Abbott's Meridia may heighten concerns for all weight-loss drugs

08:15AM 11/23/09

Article

Biotech Stock Mailbag: FDA Playbook

By Adam Feuerstein

Smart drug and biotech companies keep the FDA abreast of their clinical trial program throughout the long drug-development process.

06:01AM 11/20/09

Article

U.S. Sees Low Demand for BioCryst Flu Drug

By Adam Feuerstein

Peaking flu season could mean no need for further peramivir orders.

11:12AM 11/18/09

Article

Another Genzyme Drug Goes Kaboom: BioBuzz

By Adam Feuerstein

Company halts development of kidney disease drug following poor test results.

08:05AM 11/18/09

Article

Vivus Seeks Faster ED Drug: Biobuzz

By Adam Feuerstein

Company says ED drug met all goals in phase III study.

06:42AM 11/18/09

Article

Genzyme's Termeer: Worst Biotech CEO of '09

By Adam Feuerstein

Genzyme CEO Henri Termeer is Adam Feuerstein's Worst Biotech CEO of the Year for 2009.

12:31PM 11/17/09

Article

Isis Cholesterol Drug Effective, but Safety a Worry: BioBuzz

By Adam Feuerstein

Mipomersen lowers cholesterol but not without liver side effects.

10:56AM 11/17/09

Article

InterMune Hep C Drug Hit With Liver Tox Worry: BioBuzz

By Adam Feuerstein

Safety monitors force change to mid-stage study of ITMN-191

09:11AM 11/17/09

Page 2 of 405
Dow Jones S&P 500 NASDAQ 10-Year Note
10,366.15 1,099.92 2,173.14 33.80
Oil *
77.73
DOWN
86.53
DOWN
9.32
DOWN
11.89
UP
0.57
10 Yr
3.38%
SPDR Gold
118.70
-0.83%
-0.84%
-0.54%
+1.72%
Data delayed 20 minutes

Brokerage Partners